Loading…
The company reached a significant achievement in its FAP treatment study.
Biodexa Pharmaceuticals Plc (BDRX) announced a major milestone for its Serenta registrational Phase 3 trial in Familial Adenomatous Polyposis (FAP). The trial has reached a significant achievement, marking progress in the development of Serenta as a potential treatment for FAP.
The announcement did not include specific financial figures, share considerations, or comparisons to previous trials. The free float of Biodexa Pharmaceuticals Plc stands at 605,875 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.